title: Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.
abstract: OBJECTIVE
  Meta-analyses and large cohort studies provide confusing results on the association of the CYP3A5 6986A>G allelic variant and adverse outcomes in kidney transplant recipients under tacrolimus-based immunosuppressive regimen. A residual effect of CYP3A5 recipient genotype is unexpected if kidney transplant recipients have similar exposure of tacrolimus.
  
  
  METHODS
  We have undertaken a population-based, observational study, to investigate all the consecutive patients who received a kidney transplant at the Necker hospital between 2005 and 2015, who were treated with tacrolimus and for whom the CYP3A5 genotype was available.
  
  
  CONCLUSIONS
  We analyzed 577 patients followed for up to 5 years. We found a significant association of CYP3A5 genotypes with tacrolimus daily dose as well as with tacrolimus dose-adjusted concentrations. We however found no association of CYP3A5 genotypes with histology scores on biopsies, measured renal function, biopsy-proven acute rejection episodes and graft survival.
authors.affiliation: College de France, Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis & Cardiovascular Functions, CIRB, INSERM U1050, Paris, France.
authors.forename: Adrien
authors.initials: A
authors.lastname: Flahault
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France.|Department of Nephrology & Kidney Transplantation, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
authors.forename: Dany
authors.initials: D
authors.lastname: Anglicheau
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France.|Clinical Chemistry Department, Hôpital Européen Georges Pompidou Assistance Publique Hôpitaux de Paris, Paris, France.
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Loriot
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France.|Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Thervet
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France.|Clinical Chemistry Department, Hôpital Européen Georges Pompidou Assistance Publique Hôpitaux de Paris, Paris, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Pallet
mesh_terms: D000483:Alleles; D015331:Cohort Studies; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D014644:Genetic Variation / Q000235:genetics*; D006084:Graft Rejection / Q000235:genetics / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000639:trends*; D008297:Male; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D016559:Tacrolimus
keywords: CYP3A5; kidney transplantation; outcome; tacrolimus